Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Suspended Not applicable Interventional

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

NCT02993068
View directory record Official record
Conditions
BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma
Interventions
Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

NCT01846091
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Head and Neck Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer

NCT00647790
View directory record Official record
Conditions
Breast Cancer
Interventions
PET scan with injection of 5-8 mCi of 18FES
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 2 Interventional Results available

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

NCT02636582
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
Other · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

NCT00478686
View directory record Official record
Conditions
Breast Cancer
Interventions
Phlebotomy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

NCT06106282
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Recruiting Not applicable Interventional

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

NCT03796559
View directory record Official record
Conditions
Breast Cancer, Axillary Lymph Nodes
Interventions
Magseed Marker
Device
Lead sponsor
Endomagnetics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Terminated No phase listed Observational

Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment

NCT02887196
View directory record Official record
Conditions
Breast Neoplasms, Body Weight Changes
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Terminated Phase 1 Interventional

Phase I Study of the Combination of MLN9708 and Fulvestrant

NCT02384746
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, MLN9708
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Female Cancer Patients' Preference For Sexual Health Interventions

NCT01084642
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 23, 2026, 8:26 AM EDT
Recruiting Not applicable Interventional

Strength After Breast Cancer

NCT06052488
View directory record Official record
Conditions
Breast Cancer
Interventions
Strength After Breast Cancer
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Not applicable Interventional

Compass Course: Efficacy Study

NCT03442686
View directory record Official record
Conditions
Breast Cancer
Interventions
Compass Course
Behavioral
Lead sponsor
Allina Health System
Other
Eligibility
25 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Golden Valley, Minnesota • Minneapolis, Minnesota • Shoreview, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Enrolling by invitation No phase listed Observational

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

NCT05160480
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Neuroendocrine Tumors
Interventions
Total-body PET imaging
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Creation of the BioBank, Early Detection and Discovery Biomarkers

NCT00901680
View directory record Official record
Conditions
Pancreatic Cancer, Head and Neck Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
Not listed
Enrollment
3,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

NCT05501769
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471 in combination with Everolimus
Drug
Lead sponsor
Arvinas Estrogen Receptor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
San Diego, California • Santa Monica, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Experience of Arab American Women With Breast Cancer: In-depth Interviews

NCT02710058
View directory record Official record
Conditions
Breast Cancer
Interventions
one-time qualitative assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 23, 2026, 8:26 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Digimed Oncology PharmacoTherapy Registry

NCT04088955
View directory record Official record
Conditions
Colon Cancer, Breast Cancer, Rectal Cancer
Interventions
DigiMeds
Other
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 23, 2026, 8:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

NCT00508443
View directory record Official record
Conditions
Spinal Neoplasms
Interventions
Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

NCT06465368
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Recruiting No phase listed Observational

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774
View directory record Official record
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00470301
View directory record Official record
Conditions
Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
tipifarnib, paclitaxel, doxorubicin, cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Tampa, Florida • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology

NCT02756767
View directory record Official record
Conditions
Patients With Lung, Breast, Head and Neck, or Pelvic Malignancies
Interventions
Survey
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Terminated Phase 3 Interventional

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

NCT00082095
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pegylated liposomal doxorubicin, Capecitabine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
60 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
27
States / cities
Fountain Valley, California • Oxnard, California • Soquel, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 23, 2026, 8:26 AM EDT
Completed No phase listed Observational

Wide-field Optical Coherence Tomography Imaging of Excised Breast Tissue.

NCT04242277
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Investigational WF-OCT device
Device
Lead sponsor
Perimeter Medical Imaging
Industry
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 23, 2026, 8:26 AM EDT